Genetic engineering of B cells to create antibodies against viral infections
Targeted genetic engineering of B cells to induce protective antibody responses to viral pathogens
This study is exploring a new way to help your body fight off viruses like the flu by using special techniques to boost the production of protective antibodies, which could lead to better treatments for viral infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10884501 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune response to viral infections by genetically modifying B cells to produce protective antibodies. The approach involves using a synthetic nanoparticle to facilitate the genetic engineering process, which aims to improve the production of antibodies against respiratory viruses like influenza and RSV. By leveraging innovative techniques, the research seeks to overcome current limitations in vaccine development and antibody production. Patients may benefit from this work as it could lead to more effective treatments for viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for severe viral infections, such as those with compromised immune systems or chronic respiratory conditions.
Not a fit: Patients who are not at risk for viral infections or those with fully functioning immune systems may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the body's ability to fight off viral infections through improved antibody production.
How similar studies have performed: Previous research has shown success in using genetic engineering to produce protective antibodies against viruses, indicating a promising avenue for further exploration.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Adair, Jennifer Eileen — Fred Hutchinson Cancer Center
- Study coordinator: Adair, Jennifer Eileen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.